» Articles » PMID: 10594386

Lipid Emulsions As a Novel System to Reduce the Hemolytic Activity of Lytic Agents: Mechanism of the Protective Effect

Overview
Journal Eur J Pharm Sci
Specialties Chemistry
Pharmacology
Date 1999 Dec 14
PMID 10594386
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The hemolytic activity of sodium oleate, a high lytic agent, was investigated in different surfactant solutions and lipid emulsion formulations. A new explanation of the protective function of these systems is proposed. It was found that the hemolytic activity of the lytic agent was greatly decreased in solutions and/or dispersions with the surfactant Cremophor EL, Solutol H16 and phospholipids, which can usually build a micellar or liposomal structure. In the case of F68, where the micelle formation is still controversial, the hemolytic activity of the lytic agent was practically not affected and complete hemolysis was observed. In contrast to this, all emulsion formulations, independent of the emulsifier type, showed a stable erythrocyte behavior. Additionally, in the case of lipid emulsions only, a larger amount of the lytic agent could be added without any remarkable increase in the hemolytic activity. As an explanation for these effects it is proposed that the lytic agent is either incorporated into the lipophilic core or intercalates between the emulsifier molecules at the interface. This decreases the direct contact of the lytic agent with the erythrocyte membrane. As a result, the erythrocytes will effectively be protected from hemolytic damage, which can otherwise be induced by such substances.

Citing Articles

The Development of Magnolol-Loaded Intravenous Emulsion with Low Hepatotoxic Potential.

Gostynska A, Czerniel J, Kuzminska J, Zolnowska I, Brzozowski J, Krajka-Kuzniak V Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765070 PMC: 10537714. DOI: 10.3390/ph16091262.


A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems.

Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P RSC Adv. 2022; 10(45):26777-26791.

PMID: 35515778 PMC: 9055574. DOI: 10.1039/d0ra03491f.


Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders.

Lee M, Lee I, Wang K Biomedicines. 2022; 10(1).

PMID: 35052837 PMC: 8773368. DOI: 10.3390/biomedicines10010158.


Biosynthesis and characterisation of solid lipid nanoparticles and investigation of toxicity against breast cancer cell line.

Sharifalhoseini M, Es-Haghi A, Vaezi G, Shajiee H IET Nanobiotechnol. 2021; 15(8):654-663.

PMID: 34694719 PMC: 8675850. DOI: 10.1049/nbt2.12062.


Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB.

Satapathy M, Yen T, Jan J, Tang R, Wang J, Taliyan R Pharmaceutics. 2021; 13(8).

PMID: 34452143 PMC: 8402065. DOI: 10.3390/pharmaceutics13081183.